Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (30)
NITAG documentation (1591)
Reports (55)
SAGE documentation (218)
Scientific publications (112)
Systematic reviews (SYSVAC) (2750)
Regions
Africa (267)
Americas (762)
Eastern Mediterranean (48)
Europe (704)
South-East Asia (78)
Western Pacific (196)
Diseases
Chikungunya (9)
Cholera (33)
COVID-19 (1481)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4756 results found
2021
∙
Health Council of the Netherlands
Executive summary of the Vaccination against rotavirus
2021
∙
NACI
Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply - 7 April, 2021
2021
∙
ACIP
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Janssen COVID-19 Vaccine
2021
∙
Julia Gargano, ACIP
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Janssen COVID-19 Vaccine
2021
∙
NACI
Guidance on booster COVID-19 vaccine doses in Canada – Update December 3, 2021
2021
∙
NACI, Public Health Agency of Canada
Guidance on the prioritization of key populations for COVID-19 immunization
2021
∙
Haute Autorité de Santé
HAS opinion relating to the launch of the 2021/2022 vaccination campaign against seasonal influenza in France in the northern hemisphere and in Mayotte in the context of the 'Covid-19 epidemic - May 12, 2021.
2021
∙
Haute Autorité de Santé
HAS recommendation on Place of Moderna's Spikevax® mRNA vaccine in 12 to 17 year olds - July 28, 2021
2021
∙
Haute Autorité de Santé
HAS recommendation on the place of a booster with the COMIRNATY mRNA vaccine
2021
∙
Haute Autorité de Santé
HAS recommendation on Vaccination strategy against Covid-19 - Place of the COMIRNATY® mRNA vaccine in 12-15 year olds - 3 June, 2021
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register